Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells

Journal of Immunology

Volumn 166, Issue 11, 2001, Pages 6491-6499

  Donepudi, Manjula ^a   Raychaudhuri, Pradip ^a   Bluestone, Jeffrey A ^b   Mokyr, Margalit B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; ENHANCER REGION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; RNA SYNTHESIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR CELL LINE;

EID: 0035338811     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.11.6491     Document Type: Article

References (57)

1. Berd, D., and M. J. Mastrangelo. 1988. Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest. 6:337.
2. + T cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Res. 49:4597.
3. + suppressor T-cells. Cancer Res. 49:1649.
4. Nagarkatti, M., D. M. Toney, and P. S. Nagarkatti. 1989. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor. Cancer Res. 49:6587.
5. + T cells to cause regression of an advanced lymphoma. Immunology 71:90.
6. Yuan, L., Y. Kuramitsu, Y. Li, M. Kobayashi, and M. Hosokawa. 1995. Restoration of interleukin-2 production in tumor-bearing rats through reducing tumor-derived transforming growth factor β by treatment with bleomycin. Cancer Immunol. Immunother. 41:355.
7. Lattime, E. C., M. J. Mastrangelo, O. Bagasra, W. Li, and D. Berd. 1995. Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol. Immunother. 41:151.
8. Gorelik, L., Y. Bar-Dagan, and M. B. Mokyr. 1996. Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells. J. Immunol. 156:4298.
9. Inagawa, H., T. Nishizawa, T. Honda, T. Nakamoto, K. Takagi, and G. Soma. 1998. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions. Anticancer Res. 18:3957.
10. Bass, K. K., and M. J. Mastrangelo. 1998. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol. Immunother. 47:1.
11. Mokyr, M. B., T. V. Kalinichenko, L. Gorelik, and J. A. Bluestone. 1998. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor. J. Immunol. 160:1866.
12. Lenschow, D. J., G. H. Su, L. A. Zuckerman, N. Nabavi, C. L. Jellis, G. S. Gray, J. Miller, and J. A. Bluestone. 1993. Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. Sci. USA 90:11054.
13. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
14. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1145.
15. Sojka, D. K., M. Donepudi, J. A. Bluestone, and M. B. Mokyr. 2000. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J. Immunol. 164:6230.
16. Gorelik, L., and M. B. Mokyr. 1995. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon γ in the therapeutic outcome. Cancer Immunol. Immunother. 41:363.
17. Kalinichenko, T. V., and M. B. Mokyr. 1998. Limited importance of CD40/ CD40L interaction in the B7-dependent generation of anti-MOPC-315 cytotoxic T lymphocyte activity by tumor bearer splenic cells stimulated in vitro in the presence of tumor necrosis factor. Cancer Immunol. Immunother. 46:293.
18. La Motte, R. N., M. A. Rubin, E. Barr, J. M. Leiden, J. A. Bluestone, and M. B. Mokyr. 1996. Therapeutic effectiveness of the immunity elicited by P815 tumor cells engineered to express the B7-2 costimulatory molecule. Cancer Immunol. Immunother. 42:161.
19. Ben-Efraim, S., R. C. Bocian, M. B. Mokyr, and S. Dray. 1983. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunol. Immunother. 15:101.
20. Schreck, R., P. Rieber, and P. A. Baeuerle. 1991. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-KB transcription factor and HIV-1. EMBO J. 10:2247.
21. Verhasselt, V., W. Vanden Berghe, N. Vanderheyde, F. Willems, G. Haegeman, and M. Goldman. 1999. N-acetyl-L-cysteine inhibits primary human T cell responses at the dendritic cell level: association with NF-κB inhibition. J. Immunol. 162:2569.
22. May, M. J., F. D'Acquisto, L. A. Madge, J. Glöckner, S. Pober, and S. Ghosh. 2000. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IkB kinase complex. Science 289:1550.
23. Osborn, L., S. Kunkel, and G. J. Nabel. 1989. Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc. Natl. Acad. Sci. USA 86:2336.
24. Selvakumar, A., P. C. White, and B. Dupont. 1993. Genomic organization of the mouse B-lymphocyte activation antigen B7. Immunogenetics 38:292.
25. Zhao, J., G. J. Freeman, G. S. Gray, L. M. Nadler, and L. H. Glimcher. 1996. A cell type-specific enhancer in the human B7.1 gene regulated by NF-κB. J. Exp. Med. 183:777.
26. Baeuerle, P. A., and T. Henkel. 1994. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12:141.
27. Morel, A., N. Fernandez, A. de La Coste, H. Haddada, M. Viguier, B. S. Polla, B. Antoine, and A. Kahn. 1998. γ-ray irradiation induces B7.1 costimulatory molecule neoexpression in various murine tumor cells. Cancer Immunol. Immunother. 46:277.
28. Pahl, H. L., and P. A. Baeuerle. 1994. Oxygen and the control of gene expression. Bioessays 16:497.
29. Vereecque, R., G. Buffenoir, R. Gonzalez, N. Cambier, D. Hetuin, F. Bauters, P. Fenaux, and B. Quesnel. 2000. γ-ray irradiation induces B7.1 expression in myeloid leukaemic cells. Br. J. Haematol. 103:825.
30. Gorman, A., A. McGowan, and T. G. Cotter. 1997. Role of peroxide and superoxide anion during tumour cell apoptosis. FEBS Lett. 404:27.
31. + T cell-dependent mechanism. J. Immunol. 162:4817.
32. Meyer, M., H. L. Pahl, and P. A. Baeuerle. 1994. Regulation of the transcription factors NF-κB and AP-1 by redox changes. Chem. Biol. Interact. 91:91.
33. 2 and antioxidants have opposite effects on activation of NF-κB and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 12:2005.
34. Pinkus, R., L. M. Weiner, and V. Daniel. 1996. Role of oxidants and antioxidants in the induction of AP-1, NF-κB, and glutathione S-transferase gene expression. J. Biol. Chem. 271:13422.
35. Zhang, H., D. Haasch, K. B. Idler, and G. F. Okasinski. 1996. Isolation and promoter mapping of the gene encoding murine co-stimulatory factor B7-1. Gene 183:1.
36. Hsing, Y., B. S. Hostager, and G. A. Bishop. 1997. Characterization of CD40 signaling determinants regulating nuclear factor-κB activation in B lymphocytes. J. Immunol. 159:4898.
37. Ghosh, S., M. J. May, and E. B. Kopp. 1998. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16: 225.
38. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707.
39. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X. Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. M. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity 2:523.
40. Tsuyuki, S., J. Tsuyuki, K. Einsle, M. Kopf, and A. J. Coyle. 1997. Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness. J. Exp. Med. 185: 1671.
41. Stremmel, C., E. A. Greenfield, E. Howard, G. J. Freeman, and V. K. Kuchroo. 1999. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J. Exp. Med. 189:919.
42. Girvin, A. M., M. C. Dal Canto, L. Rhee, B. Salomon, A. Sharpe, J. A. Bluestone, and S. D. Miller. 2000. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J. Immunol. 164:136.
43. + T lymphocytes in the P815 tumor system in vitro. J. Immunol. 156:465.
44. Seo, A., F. Ishikawa, H. Nakano, H. Nakazaki, K. Kobayashi, and T. Kakiuchi. 1999. Enhancement of B7-1 (CD80) expression on B-lymphoma cells by irradiation. Immunology 96:642.
45. Rutault, K., C. Alderman, B. M. Chain, and D. R. Katz. 1999. Reactive oxygen species activate peripheral blood dendritic cells. Free Radic. Biol. Med. 26:232.
46. Pahl, H. L. 1999. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18:6853.
47. Schmidt, K. N., E. B. Traenckner, B. Meier, and P. A. Baeuerle. 1995. Induction of oxidative stress by okadaic acid is required for activation of transcription factor NF-κB. J. Biol. Chem. 270:27136.
48. Aruoma, O. I., B. Halliwell, B. M. Hoey, and J. Butler. 1989. The antioxidant action of N-acetyleysteine: its reaction with hydrogen peroxide, hydroxyl radical. superoxide, and hypochlorous acid. Free Radic. Biol. Med. 6:593.
49. Cotgreave, I. A. 1997. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv. Pharmacol. 38:205.
50. Foletta, V. C., D. H. Segal, and D. R. Cohen. 1998. Transcriptional regulation in the immune system: all roads lead to AP-1. J. Leukocyte Biol. 63:139.
51. Gilmore, T. D. 1999. The Rel/NF-κB signal transduction pathway: introduction Oncogene 18:6842.
52. Chen, F. E., and G. Ghosh. 1999. Regulation of DNA binding by Rel/NF-κB transcription factors: structural views. Oncogene 18:6845.
53. Chen, Y. Q., S. Ghosh, and G. Ghosh. 1998. A novel DNA recognition mode by the NF-κB p65 homodimer. Nat. Struct. Biol. 5:67.
54. Li, X.-H., X. Fang, and R. B. Gaynor. 2001. Role of IKKγ/NEMO in assembly of the 1κB kinase complex. J. Biol. Chem. 276:4494.
55. Doly, J., A. Civas, S. Navarro, and G. Uze. 1998. Type I interferons: expression and signalization. Cell. Mol. Life Sci. 54:1109.
56. Kirchhoff, S., D. Wilhelm, P. Angel, and H. Hauser. 1999. NFΘB activation is required for interferon regulatory factor-1-mediated interferon β induction. Eur. J. Biochem. 261:546.
57. Gallucci, S., and P. Matzinger. 2001. Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13:114.